BlossomHill Therapeutics (NASDAQ:BLSM) Upgraded by Leerink Partners to Strong-Buy Rating

Leerink Partners upgraded shares of BlossomHill Therapeutics (NASDAQ:BLSM) to a strong-buy rating in a report issued on Tuesday,Zacks reports.

A number of other equities analysts have also recently commented on the stock. Wall Street Zen raised shares of BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright began coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They issued a “buy” rating and a $35.00 price target for the company. JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $28.00 price target for the company. Guggenheim began coverage on BlossomHill Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Lifesci Capital initiated coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $32.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. Based on data from MarketBeat.com, BlossomHill Therapeutics has an average rating of “Strong Buy” and a consensus target price of $32.20.

BlossomHill Therapeutics Stock Performance

BlossomHill Therapeutics stock opened at $18.99 on Tuesday. BlossomHill Therapeutics has a 1 year low of $15.25 and a 1 year high of $20.61.

Insider Transactions at BlossomHill Therapeutics

In related news, Director Orbimed Advisors Llc bought 625,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the transaction, the director owned 2,714,279 shares of the company’s stock, valued at $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Vincent Paul Liptak acquired 2,200 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $35,200.00. Following the transaction, the general counsel owned 111,412 shares of the company’s stock, valued at $1,782,592. This represents a 2.01% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics News Roundup

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Leerink Partners, HC Wainwright, and Guggenheim each upgraded BlossomHill Therapeutics to “strong-buy,” strengthening the analyst consensus around the company. Zacks analyst upgrade coverage
• Positive Sentiment: Lifesci Capital initiated coverage with an “outperform” rating and a $32 price target, implying substantial upside from the current level. Benzinga coverage initiation
• Positive Sentiment: JPMorgan initiated coverage with an “overweight” rating and a $28 price target, adding another major-bank endorsement and signaling confidence in BlossomHill’s growth prospects. Tickerreport JPMorgan coverage
• Positive Sentiment: BlossomHill will present updated Phase 1/2 SOLARA trial data for BH-30643 at the 2026 World Conference on Lung Cancer. The presentation will cover anti-tumor activity in EGFR-mutant non-small-cell lung cancer patients with resistance mutations such as C797S. BH-30643’s FDA Fast Track designation and its potential to address an area without approved oral targeted therapies provide important pipeline catalysts. BlossomHill SOLARA trial data announcement
• Positive Sentiment: A report highlighted insider buying of BlossomHill shares, which may be viewed as a signal of management confidence ahead of upcoming clinical and corporate catalysts. Insider buying report

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.